siRNA treatment lowers triglycerides in patients with rare disorder

.STUDY FEATURE.19 September 2024.

Plozasiran minimized triglyceride degrees by 80% and also reduced the threat of pancreatitis in clients along with consistent chylomicronemia, with or without a hereditary prognosis.